Philip Morris International Inc. (NYSE: PM) saw its stock climb 6.5% to $182.11 on Monday, following the U.S. Food and Drug Administration's (FDA) announcement that it would not prioritize enforcement action against certain nicotine pouch and e-cigarette products that have pending premarket tobacco product applications (PMTAs). The move has rekindled investor optimism regarding the launch of ZYN Ultra, a new variant of the company's popular nicotine pouch brand.
The FDA's guidance, issued on May 8, outlines that the agency will generally refrain from enforcement against products that have filed a PMTA and are still under review, provided they do not target youth or exhibit other safety concerns. While the agency emphasized that this policy is not a full authorization and could change, the market interpreted it as a green light for Philip Morris to move forward with its smoke-free product pipeline.
This development is particularly significant for Philip Morris, as first-quarter U.S. shipments of ZYN pouches fell 23.5% year-over-year, partly due to regulatory delays. The company had previously signaled its intention to introduce ZYN Ultra to the U.S. market, but the product remained stuck in FDA review limbo. Analysts at Goldman Sachs, who maintain a Buy rating on Philip Morris and consider it a top pick, noted that the new policy could allow ZYN Ultra to reach store shelves within months.
The stock's rally outpaced gains from peers Altria Group and British American Tobacco, whose U.S.-listed shares saw more modest upticks. This reflects the market's view that Philip Morris stands to benefit disproportionately from the regulatory shift, given its heavy investment in smoke-free alternatives.
Despite the positive sentiment, the FDA's guidance comes with important caveats. The policy is not legally binding, and the agency can still take enforcement action against products with youth-oriented designs, elevated nicotine levels, or other safety red flags. Moreover, the guidance does not guarantee eventual PMTA approval for ZYN Ultra or similar products.
Philip Morris is also facing competitive pressure from British American Tobacco's Velo brand, which has been gaining traction in the oral nicotine category. Jefferies analyst Andrei Andon-Ionita recently flagged that ZYN volumes are losing momentum, with Velo poised to capture additional market share. This dynamic underscores the urgency for Philip Morris to accelerate its product rollout.
In its first-quarter earnings report, Philip Morris posted net revenues of $10.1 billion, up 9.1% year-over-year, with smoke-free products accounting for 43% of total net revenue. Adjusted diluted earnings per share rose 16% to $1.96. CEO Jacek Olczak expressed confidence in the company's growth trajectory, emphasizing the strong performance of its IQOS heated-tobacco system.
At the company's annual meeting, shareholders approved all director nominees and executive compensation, while a proposal to cover cigarette-filter cleanup costs was rejected. The company reported 2025 net revenues exceeding $40 billion, with smoke-free contributions nearing $17 billion.
The path ahead for Philip Morris hinges on the speed of ZYN Ultra's market entry and consumer adoption. If the product launches swiftly and gains traction, Monday's rally could mark the beginning of a sustained upswing for the stock. Conversely, prolonged regulatory processes or intensifying competition from Velo could limit the gains to a temporary boost.
